Member Info for chester18

Might be irrelevant but the last update was 17th September 2025 which means next Wednesday is exactly 9 months.

That’s an awful lot of data to be shared especially the scan results and the level of PFS.

When it does arrive it will probably be a comprehensive update as the ModiFY trial ‘Primary Completion(Estimated) is the 1st July 2026’.

My hopes are that the study is progressing nicely with solid evidence that ModiTope is another potential game-changer in the battle against solid tumours.

The ‘Adjuvant / Neo-Adjuvant’ Arm ( 15 patients in each ) of the trial will be extremely important.

GLA

If Phil’s promise that the Modi1 update will happen in the 2nd Quarter of 2026 is kept, we only have a maximum of 17 trading days to wait.

Having followed the to’s and fro’s of the company for a minimum of 15 years I can definitely wait another 17 trading days for any positive news.

With so many potential avenues for our BoD to consider the longer this goes on the more confident I am that the final outcome will be extremely exciting for shareholders.

The difficulty is living each and every day until that positive news arrives if you are fixated on every days individual share movements.

My advise is hold tight and enjoy these last days of being skint 🤣🤣🤣

A Very good point Ray

It just seems to me that the GenMab / GlyMab deal is taking a long time to move forward. Bermudashorts posted about GenMab being sidetracked recently because of an acquisition which could have put our targets on hold.

That would just be our luck, again.

Having manufactured a ‘trial sample’ sized batch you would hope it compelled them to push forward to achieve approval for a ph1 clinical trial.

The Scancell board will know that they cannot keep the lid on all things for much longer. If we are to start the Ph3 in 2026 the clock is ticking …….

GLA.

I should have written :

Does anyone have any thoughts ?

Morning C11

We are definitely in ‘what if’ territory…

Many thoughts that unfortunately become too tenuous at times.

One interesting fact is that Scancell said at the AMG ( I think it was Lindy ) that GenMab had actually manufactured a trial sample batch of one of our target GlyMabs.

In overall inference was that GenMab would be going forward and I took that as a possible Phase1 registration, triggering one of the milestone payments.

That comment was now over 6 months ago and I’m wondering 🤔, would Scancell have to own up to receiving a milestone or not ?

Could an NDA with GenMab allow for silence on that potential payment ?

Any thoughts !

Those two trades at £20k is the perfect ISA combo. Even the difference is exactly the kind of cost involved to sell and re-buy.

We have entered an ever contracting space where each trading day the tension becomes ever more palpable.

This is where the reality of Scancell’s discussion’s will hinge on who is interested in what and at what price.

The approval by MHRA is just a matter of time and the question of temporary funding is probably already in place.

Just how well is Modi1 doing ?

Are GenMab seeing outstanding results with our GlyCan Targets ?

Can the likes of BMS, Merck or BionTech allow Scancell to go it alone and become a real threat to their future markets and revenues ?

Have Redmile set a high price that covers Scancell’s full potential over the next 10 years ?

If Large Pharma don’t like that price have Redmile already laid out a path to a NasDaq listing ?

Fund the SCOPE Ph3, push forward with Modi1, GlyMab’s and get SC134 into a Ph 1/2 clinical trial and in 18 months to 2 years launch on the NasDaq as a fully commercial company with huge revenue potential ?

So the question really is, have I written a fantasy or am I scratching at the surface of reality ?

Place your bets, are you in or out ????

Having just run through that January 2026 Presentation these are the possibilities for future financing as it stands.

GlyMab Theraputics Ltd is sold / partnered generating enough upfront cash to support its development and cover the initial costs of the SCOPE Ph3 Trial.

iScib1+ is either partnered or possibly sold along with the whole Immunobody Platform.

Modi1 data is so good that we can license out in Renal Cell Carcinoma or Head & Neck to generate funding for the SCOPE Ph3.

Scancell’s technology is so compelling that the whole company is taken over in a large cash deal.

And I’ve not mentioned AvidiMab or SC134 or the ‘hinted at’ improvements in both effectiveness and targeting.

So our board have a multitude of potential avenues to explore and keep all the potential suitors on their toes. Which should mean they can realise the highest possible value for whichever way they decide is the best route forward.

Redmile and Vulpes will also have their combined say in any decisions.

GLA.

I have just rewatched the SparkLive Presentation from 29th January 2026.

When asked about the Modi1 trial in the Q&A session a couple of important comments were made :

A ) The maturity of the PFS data and if that data is clearly positive it would encourage Large Pharma to License out Modi1 in Renal Cell Carcinoma. That read out is scheduled for H1/26 so in the next few weeks.

B ) The enrolment for that study was virtually complete at the end of January 2026. This is important because any discussions happening right now about the relevant data are not trying to estimate on a partial enrolment.

Phil also intimated that the maturity of the PFS data was extremely important when thinking about the potential to license out and generate finance from the ModiFY trial.

GLA

Modi1 Trial Phase 1 / 2

Start date : 7th April 2022

Primary Completion(Estimated) 1st July 2026

Study Completion (Estimated) 1st July 2027

Enrolment (Estimated) 168

People selling out and for why ?

Hopefully it’s just traders having to make that call, I do hope it’s not anyone panicking..

Let’s just put things into perspective…..

Tuesday 2nd June 2026

GenMab Update : Overdue

Glycan Therapeutics Update : Overdue

MHRA Approval for Ph3 : Due at anytime

iScib1+ further PFS data scheduled

Modi1 Clinical Update : June 2026

Funding to begin the Ph3 Trial and run the company for the next year or two : Overdue

Information about the ongoing discussions with several potential partners / investors : Overdue

Conclusion : Scancell are not in a legal position to enlighten the market on any of the above because details about the future of the company are being worked out. ASCO is the perfect cover to bring top executives together to thrash out a deal in person. So don’t despair because there is no news as the silence could just mean discussions are ongoing.

‘Isn’t it amazing how from such misunderstandings blossom’s the greatest of friendships’ C18 about CrustyPete and EmptyEnd 01/06/2026

“If you two turn up at the £1.50 a share party I don’t want any scrapping, thank you very nicely”……

Yes VanVan

Why would Scancell not be ‘shouting from the rooftops’ at such an event. The whole world is there to listen.

GLA

Hi Ray

Don’t forget the tenacity we have shown to battle on with cry’s of ‘Cardboard Labs’ and ‘Lifestyle Country Bumpkin Science’. ……

Those of us that actually saw what Immunobody and ModiTope were capable of long term stood by the science.

Both platforms have benefited from the rise of Checkpoint Inhibitors in late stage cancers but both will be so useful as Mono therapies in the future. Especially in earlier stages of cancers where the tumours are much less mutated and present as lesser opponents to Scancell’s immunotherapy.

Well this will all come to pass once MHRA have finally given their blessing.

EE

The fact that Scancell with all the advancement in the data, especially the PFS figures, are not making some kind of a splash at this years ASCO is very suspicious.

Your prediction for tonight is therefore not unfounded just way above what I can realistically hope for.

As I commented on earlier, “can such a deal be concluded without that crucial MHRA approval” ? I suppose it could if there was enough commercial pressure to win Lindy’s signature.

Somebody said that any such deal would happen during ASCO and be announced later next week.

All things possible but I would definitely, most definitely in fact absolutely would not be out of Scancell this weekend.

That’s my only advice and solely my opinion based on the ASCO no show.

GLA ….. 👊

Morning, this is probably the most considered issue by all Scancell shareholders other than those with a seat on the board.

When Phil set out his vision for when Modi1 would be updated I'm sure he expected the trial approvals from MHRA and EMA to be a matter of swift progress.

Can a deal be signed off without those approvals ?

June is now loaded with expectations but for me the key is the MHRA authority to proceed in the UK.

Modi1 update will have take its place behind this crucial SCOPE approval.

The positive is that Phil intimated that the issues holding up the decision are small but necessary in the eyes of MHRA, so the vast majority of clinical detail has been worked through. On that basis I expect a hugely relieved CEO announcement in the next couple of weeks. Everything else then falls into place and Modi1 update arrives as promised H1/26.

GLA

Not blowing the trumpets at ASCO means they don’t need to. It is the single loudest clue that we are deep into deal-making.

How that turns out is the big question but the bare minimum will be that we have secured the means to run the Ph3.

I hope it comes with enough cash headroom to speedily progress the ModiFY Trial and push SC134 into Ph1 🤞🤞

Violindog

Let’s see what happens when the MHRA finally stop dragging their combine feet and sanction the SCOPE Phase 3 trial. Maybe it will even contain the understanding that Adjuvant and Neo-Adjuvant can be added to the trial at some point.

We cannot be that far away maybe just a few more weeks 🤞🤞

GLA

There so many possibilities as to where the Phase 3 finance will be derived from.

Our board must have had many closed door discussions about the ‘pros & cons’ of each avenue forward.

As a shareholder I would welcome a deal that allows me to continue with part of my investment, to stay onboard as the science is proven and company begins to expand commercially.

If Scancell is taken out in one large deal then I’ll just have to accept that money talks and be content that I’ve supported four cash raises in the past, so I’ve done my bit.

Anyway it’s all conjecture at the moment but what is definitely on the way is the promised Modi1 trial update.

Promised H1/26.

👍👍

As Cleanerworld has pointed our CEO Phil L’Huillier is listed as a Keynote Speaker at UK Biotech Day on 27–28 May.

ASCO 2026 conference starts this Friday 29th May until Tuesday 2nd June.

*A Keynote Speech followed by a conference that Scancell would normally make every effort to attend and have submitted Posters in the recent past*.

With my amazing ability to join any two dots no matter how convoluted, I have put the above two factors together and concluded ‘There Could be News’ this week.

Possibly - Maybe 🤔